Sign in
KTTAW Stock Price, Chart, Stats & News
Pasithea Therapeutics Corp.
Save
Pasithea Therapeutics Corp. (KTTAW) does not currently pay a dividend.
20,838
Market cap
–
Current P/E
–
Forward P/E
KTTAW chart
Fundamentals
Gross margin | – |
Operating margin | – |
Pretax margin | – |
Net margin | – |
Effective tax rate | – |
ROA | -99.00% |
ROE | -97.88% |
D/E | – |
Interest coverage ratio | – |
KTTAW valuation
P/E | – |
P/S | – |
P/B | 0.45x |
P/CF | -0.45x |
P/FCF | -0.45x |
P/OCF | -0.45x |
PEG | -0.02x |
EV multiple | -0.74x |
About
Pasithea Therapeutics Corp. is a biotechnology firm dedicated to exploring and developing therapies for various psychiatric and neurological conditions. Beyond its research endeavors, the company intends to establish clinics specializing in the treatment of depression. At these facilities, certified pharmacists will administer intravenous ketamine infusions, and the firm will also extend business support services for these operations.
Similar securities
Based on sector and market capitalization
Report issue